Literature summary for 3.4.21.122 extracted from

Yamamoto, M.; Matsuyama, S.; Li, X.; Takeda, M.; Kawaguchi, Y.; Inoue, J.I.; Matsuda, Z.
Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay (2016), Antimicrob. Agents Chemother., 60, 6532-6539 .

Search for more literature for 3.4.21.122

Application

Application	Comment	Organism
analysis	development of a cell-based fusion assay for the S protein in a TMPRSS2-dependent manner using cell lines expressing Renilla luciferase-based split reporter proteins. S-protein is stably expressed in the effector cells, and the corresponding receptor for S, CD26, is stably coexpressed with TMPRSS2 in the target cells. Membrane fusion between the effector and target cells is quantitatively measured by determining the Renilla luciferase activity. The assay is optimized for a 384-well format	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
Nafamostat	potent inhibitor of protein-mediated membrane fusion, blocks MERS-CoV infection in vitro	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	O15393	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)